Navigation Links
Novo Nordisk Inc. Announces Exclusive Agreement With Upsher-Smith Laboratories, Inc. to Market Vagifem® 10 mcg

PRINCETON, N.J., Aug. 23 /PRNewswire-FirstCall/ -- Novo Nordisk Inc. today announced that it has signed an exclusive agreement with Upsher-Smith Laboratories, Inc. to market Vagifem® (estradiol vaginal tablets) 10 mcg.  Under the terms of the agreement, Upsher-Smith will exclusively market Vagifem® 10 mcg to physicians in the U.S. beginning August 2 through the company's existing field sales force.

Novo Nordisk introduced Vagifem® 10 mcg to the U.S. market earlier this year.  The new dose replaces Vagifem® 25 mcg dose, which was discontinued on July 30, 2010.

"This partnership with Upsher-Smith supports the launch and conversion of the U.S. market to Vagifem® 10 mcg," said Eddie Williams, Vice President of Biopharmaceuticals at Novo Nordisk.  "Leveraging Upsher-Smith's experienced sales force, we are able to maintain our commitment to patient care and the medical community by making sure that physicians are aware of Vagifem® 10 mcg for treating menopausal women with symptoms of atrophic vaginitis."

"The alignment of our two organizations and our products, which offer low-dose estrogen treatments for menopausal women, make this a unique partnership opportunity," said Tom Burke, Executive Vice President, Commercial Operations at Upsher-Smith.  "The combined history of our two companies offers more than two centuries of experience bringing meaningful pharmaceutical products to the marketplace."

Financial terms of the agreement are not being disclosed.

Important Safety Information

What is the most important information I should know about Vagifem® (an estrogen hormone)?

  • Using estrogen-alone may increase your chance of getting cancer of the uterus (womb) Report any unusual vaginal bleeding right away while you are using Vagifem®. Vaginal bleeding after menopause may be a warning sign of cancer of the uterus (womb). Your health care provider should check any unusual vaginal bleeding to find the cause
  • Do not use estrogen-alone to prevent heart disease, heart attacks, strokes or dementia (decline of brain function)
  • Using estrogen-alone may increase your chances of getting strokes or blood clots
  • Using estrogen-alone may increase your chance of getting dementia, based on a study of women age 65 years or older
  • Do not use estrogens with progestins to prevent heart disease, heart attack, or dementia
  • Using estrogens with progestins may increase your chances of getting heart attacks, strokes, breast cancer, or blood clots
  • Using estrogens with progestin may increase your chance of getting dementia, based on a study of women 65 years and older
  • You and your health care provider should talk regularly about whether you still need treatment with Vagifem®

Vagifem® is used after menopause to treat menopausal changes in and around the vagina.

Do not start using Vagifem® if you: have unusual vaginal bleeding, currently have or have had certain cancers, had a stroke or heart attack, currently have or have had blood clots, currently have or have had liver problems, are allergic to Vagifem® or any of its ingredients, or think you may be pregnant.

The most commonly reported side effects of Vagifem® included: headache, breast pain, irregular vaginal bleeding or spotting, stomach/abdominal cramps, bloating, nausea and vomiting, hair loss, fluid retention, and vaginal yeast infection.

About Novo Nordisk

Novo Nordisk is a global healthcare company with more than 87 years of innovation and leadership in diabetes care.  The company also has leading positions within hemophilia care, growth hormone therapy and hormone therapy for women. Novo Nordisk's business is driven by the Triple Bottom Line: a commitment to social responsibility to employees and customers, environmental soundness and economic success.  Headquartered in Denmark, Novo Nordisk employs more than 29,650 employees in 76 countries, and markets its products in 179 countries.  Novo Nordisk's B shares are listed on the stock exchange in Copenhagen and its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit

About Upsher-Smith Laboratories

Upsher-Smith Laboratories, Inc., founded in 1919, is a rapidly growing, privately held pharmaceutical company that manufactures and markets branded and branded generic prescription and over-the-counter products. Upsher-Smith's product portfolio focuses in the areas of women's health, dermatology, cardiology, and central nervous system diseases. For more information, visit

© 2010 Novo Nordisk Printed in the U.S.A. August 2010

SOURCE Novo Nordisk Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Insulin Analogues From Novo Nordisk, Eli Lilly and Sanofi-Aventis Will Drive Growth in the Type 1 Diabetes Drug Market
2. Novo Nordisk New Data From a Phase 3 Study Confirms Clinical Benefits of Once-Daily Liraglutide in the Management of Type 2 Diabetes
3. Novo Nordisk Wins Design Award for NovoTwist(TM) Needle
4. Novo Nordisk is Changing Possibilities in Hemophilia
5. Novo Nordisks Victoza(R) Receives FDA Approval for Adults With Type 2 Diabetes
6. Novo Nordisk Awarded Department of Veterans Affairs National Insulin Contract
7. Novo Nordisk partners with international scientific community for Victoza(R) cardiovascular outcomes trial
8. Novo Nordisk Awards More Than $300,000 in Grants to Support Education and Community Health Programs
9. Novo Nordisk Announces Resources to Help Support Kids with Diabetes Attending Summer Camp
10. Novo Nordisk Addresses Innovation in Diabetes Care in Second Issue of Industry Resource for Information on Diabetes and Chronic Disease
11. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
Post Your Comments:
(Date:11/29/2015)... -- National Decision Support Company (NDSC) continues to experience ... statewide implementations. As a result, ordering providers now ... than 1 million times per month—all from within ... real-time feedback on the most appropriate imaging test ... at over 100 healthcare systems nationally, representing over ...
(Date:11/27/2015)... Une nouvelle approche consistant ... contre le cancer avancé.    --> ... au traitement photodynamique au Bremachlorin contre le cancer ... nouvelle approche consistant à combiner l,immunothérapie au traitement ...    Clinical Cancer Research . ...
(Date:11/27/2015)... 27, 2015 --> ... go online. The potential to save costs, improve treatment ... far from fully exploited as yet. Here, particular emphasis ... either via mobile tablet or directly at the patients, ... ) -->      (Photo: ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... 27, 2015 , ... Lizzie’s Lice Pickers just announced a special promotion that ... of their purchase of lice treatment product. In addition, customers will receive a complimentary ... spokesperson. “Finding lice is a sure way to ruin the holidays, so we encourage ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... ProSidebar: ... in Final Cut Pro X. With ProSidebar: Fasion, video editors can easily add ... ProSidebar as a minimalist title opener. Utilize presets featuring self-animating drop zones, lines, ...
(Date:11/27/2015)... ... 2015 , ... Consistent with the Radiology Business Management ... Radiology Marketing Programs meeting will showcase some of the best 2015 radiology ... Palace in Las Vegas with a pre-conference session on a collaborative approach for ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... A simply ... Jones, is an interesting show that delves into an array of issues that are ... that could benefit from open dialogue, this show is changing the subjects consumers focus ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... innovative online platform for mental health and wellness consultation, has collaborated with a ... will bridge the knowledge gap experienced by parents and bring advice from parenting ...
Breaking Medicine News(10 mins):